Extended AML Panel BCRABLAMLETO CBFB PMLRARA FLT3 NPM1 CEBPA Test
Price: 5400.0 AED
Sample Condition: Bone marrow / Peripheral blood (Transport immediately)
Report Delivery: 7-8 days
Method: Sanger Sequencing
Test Type: Genetics
Doctor: Gynecologist
Test Department: Pre Test Information
Extended AML Panel (BCR/ABL, AML/ETO, CBFB, PML/RARA, FLT3, NPM1, CEBPA) can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details
The Extended AML Panel is a set of genetic tests that are used to diagnose and monitor patients with acute myeloid leukemia (AML). This panel includes tests for mutations in the following genes:
- BCR/ABL: This gene is associated with chronic myeloid leukemia (CML), but can also be present in a small percentage of AML cases.
- AML/ETO: This gene fusion is found in about 20% of AML cases and is associated with a poorer prognosis.
- CBFB: Mutations in this gene are found in about 15% of AML cases and are associated with a better prognosis.
- PML/RARA: This gene fusion is found in about 5-10% of AML cases and is associated with acute promyelocytic leukemia (APL).
- FLT3: Mutations in this gene are found in about 30% of AML cases and are associated with a poorer prognosis.
- NPM1: Mutations in this gene are found in about 30% of AML cases and are associated with a better prognosis.
- CEBPA: Mutations in this gene are found in about 10% of AML cases and are associated with a better prognosis.
By analyzing these genes, doctors can determine the specific subtype of AML a patient has, which can help guide treatment decisions. Additionally, monitoring changes in these genes over time can help doctors assess a patient’s response to treatment and detect any potential relapse.
Test Name | Extended AML Panel BCRABLAMLETO CBFB PMLRARA FLT3 NPM1 CEBPA Test |
---|---|
Components | EDTA Vacutainer (2ml) |
Price | 5400.0 AED |
Sample Condition | Bone marrow \/ Peripheral blood (Transport immediately) |
Report Delivery | 7-8 days |
Method | Sanger Sequencing |
Test type | Genetics |
Doctor | Gynecologist |
Test Department: | |
Pre Test Information | Extended AML Panel (BCR/ABL,AML/ETO, CBFB, PML/RARA, FLT3, NPM1, CEBPA) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
Test Details |
The Extended AML Panel is a set of genetic tests that are used to diagnose and monitor patients with acute myeloid leukemia (AML). This panel includes tests for mutations in the following genes: 1. BCR/ABL: This gene is associated with chronic myeloid leukemia (CML), but can also be present in a small percentage of AML cases. 2. AML/ETO: This gene fusion is found in about 20% of AML cases and is associated with a poorer prognosis. 3. CBFB: Mutations in this gene are found in about 15% of AML cases and are associated with a better prognosis. 4. PML/RARA: This gene fusion is found in about 5-10% of AML cases and is associated with acute promyelocytic leukemia (APL). 5. FLT3: Mutations in this gene are found in about 30% of AML cases and are associated with a poorer prognosis. 6. NPM1: Mutations in this gene are found in about 30% of AML cases and are associated with a better prognosis. 7. CEBPA: Mutations in this gene are found in about 10% of AML cases and are associated with a better prognosis. By analyzing these genes, doctors can determine the specific subtype of AML a patient has, which can help guide treatment decisions. Additionally, monitoring changes in these genes over time can help doctors assess a patient’s response to treatment and detect any potential relapse. |